IQVIA (NYSE:IQV) Downgraded to Hold Rating by StockNews.com

StockNews.com cut shares of IQVIA (NYSE:IQV) from a buy rating to a hold rating in a research note released on Thursday.

A number of other equities research analysts have also recently weighed in on IQV. Leerink Partners reissued an “outperform” rating and issued a $248.00 price target (down from $260.00) on shares of IQVIA in a research report on Tuesday, November 19th. Evercore ISI dropped their price target on IQVIA from $270.00 to $265.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 8th. The Goldman Sachs Group reduced their price objective on IQVIA from $280.00 to $250.00 and set a “buy” rating for the company in a research note on Friday, November 1st. BTIG Research lowered their target price on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, JPMorgan Chase & Co. reduced their price target on shares of IQVIA from $279.00 to $240.00 and set an “overweight” rating for the company in a research report on Tuesday, November 5th. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, IQVIA has an average rating of “Moderate Buy” and an average price target of $256.50.

IQVIA Stock Down 0.3 %

Shares of NYSE IQV opened at $200.84 on Thursday. The business has a 50-day moving average of $218.67 and a two-hundred day moving average of $226.11. The company has a market capitalization of $36.45 billion, a price-to-earnings ratio of 26.36, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51. IQVIA has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81.

Institutional Trading of IQVIA

Institutional investors have recently bought and sold shares of the company. Versant Capital Management Inc increased its stake in shares of IQVIA by 733.3% during the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock worth $26,000 after purchasing an additional 110 shares in the last quarter. Opal Wealth Advisors LLC purchased a new position in IQVIA during the second quarter worth $27,000. Capital Performance Advisors LLP purchased a new stake in shares of IQVIA in the third quarter valued at $27,000. Park Place Capital Corp acquired a new stake in shares of IQVIA during the third quarter valued at $28,000. Finally, Itau Unibanco Holding S.A. purchased a new stake in IQVIA during the 2nd quarter worth about $29,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.